Compare · ARGX vs CGON
ARGX vs CGON
Side-by-side comparison of argenx SE (ARGX) and CG Oncology Inc. (CGON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and CGON operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.50B, about 9.6x CGON ($6.59B).
- Over the past year, ARGX is up 45.3% and CGON is up 178.2% - CGON leads by 132.9 points.
- ARGX has been more active in the news (15 items in the past 4 weeks vs 7 for CGON).
- ARGX has more recent analyst coverage (25 ratings vs 16 for CGON).
- Company
- argenx SE
- CG Oncology Inc.
- Price
- $1024.81-3.22%
- $74.31-5.96%
- Market cap
- $63.50B
- $6.59B
- 1M return
- +17.43%
- +1.64%
- 1Y return
- +45.32%
- +178.21%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2024
- News (4w)
- 15
- 7
- Recent ratings
- 25
- 16
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Completes Acquisition of Forte Biosciences, Inc.
- argenx upgraded by UBS with a new price target
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
Latest CGON
- Director Post Leonard E sold $74,540 worth of shares (1,000 units at $74.54) as part of a pre-agreed trading plan and exercised 1,000 shares at a strike of $0.60 (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.
- SEC Form 10-Q filed by CG Oncology Inc.
- CG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 424B5 filed by CG Oncology Inc.
- CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
- Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $71,170 worth of shares (1,000 units at $71.17) as part of a pre-agreed trading plan (SEC Form 4)
- Director Mulay James exercised 24,165 shares at a strike of $26.63 and sold $1,816,241 worth of shares (24,165 units at $75.16) as part of a pre-agreed trading plan (SEC Form 4)